Current status of xenotransplantation and prospects for clinical application
- 30 September 2009
- journal article
- review article
- Published by Wiley in Xenotransplantation
- Vol. 16 (5), 263-280
- https://doi.org/10.1111/j.1399-3089.2009.00534.x
Abstract
Xenotransplantation is one promising approach to bridge the gap between available human cells, tissues, and organs and the needs of patients with diabetes or end‐stage organ failure. Based on recent progress using genetically modified source pigs, improving results with conventional and experimental immunosuppression, and expanded understanding of residual physiologic hurdles, xenotransplantation appears likely to be evaluated in clinical trials in the near future for some select applications. This review offers a comprehensive overview of known mechanisms of xenograft injury, a contemporary assessment of preclinical progress and residual barriers, and our opinions regarding where breakthroughs are likely to occur.Keywords
This publication has 150 references indexed in Scilit:
- Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate modelProceedings of the National Academy of Sciences, 2009
- Antibody-mediated xenograft injury: Mechanisms and protective strategiesTransplant Immunology, 2009
- Human Leukocyte Transmigration Across Galα(1,3)Gal-Negative Porcine Endothelium Is Regulated by Human CD18 and CD99Transplantation, 2009
- Expression of Tissue Factor and Initiation of Clotting by Human Platelets and Monocytes After Incubation With Porcine Endothelial CellsTransplantation, 2008
- HLA-Mismatched Renal Transplantation without Maintenance ImmunosuppressionNew England Journal of Medicine, 2008
- Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppressionThe Journal of Experimental Medicine, 2007
- Role for CD47-SIRPα signaling in xenograft rejection by macrophagesProceedings of the National Academy of Sciences, 2007
- Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Gal?1?3Gal), blood group H determinant andN-glycolylneuraminic acidGlycoconjugate Journal, 1996
- Distribution of the major xenoantigen (gal(α1–3)gal) for pig to human xenograftsTransplant Immunology, 1994
- Genetically engineered pigsThe Lancet, 1993